- Biosynth has opened an expanded GMP bioconjugation facility at its Berlin site, enhancing capabilities for conjugate vaccines and drugs.
- The site upgrade includes new class D and C cleanrooms and supports full project development to commercial supply.
Biosynth has officially opened its expanded GMP bioconjugation facility in Berlin, further strengthening its global manufacturing network and CDMO services. The upgrade enhances production of conjugate vaccines and drugs, activated PEGs, and polymer-based excipients used in drug delivery.
The expansion includes the addition of class D and C cleanrooms, increasing Biosynth’s capacity to provide scalable and diverse conjugation services. The investment is described as a natural progression of the company’s Berlin operations, reflecting growth in parallel with customer demand.
Thomas Eisele, Chief Operations Officer, said: “We are thrilled to officially open the new expansion to our bioconjugation facility in Berlin, which represents a significant enhancement to our existing operations.”
The Berlin site refurbishment also improves GMP capabilities for bioconjugate manufacturing, positioning Biosynth to support projects from early process development through to commercial supply. The company’s offering spans diagnostics and therapeutic applications, in line with growing industry interest in specialised conjugation chemistry and advanced polymers.
